Israel-based Teva Pharmaceutical Industries has launched QVAR RediHaler (beclomethasone dipropionate HFA) Inhalation Aerosol in the US for the treatment and control of asthma in patients aged four and above.
This breath-actuated inhaled prescription medicine will be commercially available in strengths of 40mcg and 80mcg.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Teva North America Commercial executive vice-president Brendan O’Grady said: “QVAR has been an available asthma treatment option for well over a decade, so we are excited by the new technology of QVAR RediHaler that directly addresses an unmet need in the field of asthma management.
“By merging our breath-actuated inhaler technology with asthma medication, we hope to better serve the needs of the respiratory community and look forward to seeing the adoption of QVAR RediHaler in the coming months.”
Unlike the conventional metered-dose inhalers (MDIs), QVAR RediHaler delivers medication through a breath-actuated inhaler.
Using this inhaler technology, it administers the same active ingredient found in the earlier available QVAR (beclomethasone dipropionate HFA) Inhalation Aerosol.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataQVAR RediHaler is ready to use without the need for prior shaking or priming.
The company noted that this medicine is not indicated for the relief of acute bronchospasm and it should not be used with a spacer or volume-holding chamber due to its breath actuated medication mechanism.
Furthermore, it should not be used to relieve sudden breathing problems or as a replacement of rescue inhaler.
With the launch of QVAR RediHaler, Teva will terminate the sales of the previous version of QVAR in the US market.
